Organon & Co. (OGN)

$9.94 -0.08 (-0.80%)
Market Cap 2.58B
Revenue (ttm) 6.40B
Net Income (ttm) 864.00M
EPS (ttm) N/A
PE Ratio 2.77
Forward PE 2.69
Profit Margin 13.49%
Debt to Equity Ratio 16.52
Volume 3,566,500
Avg Vol 5,981,422
Day's Range N/A - N/A
Shares Out 259.96M
Stochastic %K 44%
Beta 0.60
Analysts Sell
Price Target $14.00

Company Profile

Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 551 430 6900
Address:
30 Hudson Street, Floor 33, Jersey City, United States
reez007
reez007 Jul. 11 at 8:03 PM
$OGN lol someone should investigate this action. Trade up to $10.08 then just tank. Sure
0 · Reply
HoosierDaddy1728
HoosierDaddy1728 Jul. 11 at 2:30 PM
$DARE Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment Daré is eligible for continued non-dilutive funding installments of up to approximately $11.2 million Market cap $21 million FDA-approved product for the treatment of bacterial vaginosis Treatment for female sexual arousal disorder set to start sales q4 Non hormonal contraceptive in phase 3 $VERU $IFRX $BTAI $OGN
0 · Reply
theDIOyears
theDIOyears Jul. 8 at 10:57 PM
$OGN still here, still buying. Things are getting tight.
2 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Jul. 7 at 11:41 AM
$OGN Organon's VTAMA Granted Strong Recommendation By American Academy Of Dermatology In Updated 2025 Guidelines For Adult Atopic Dermatitis
0 · Reply
DonCorleone77
DonCorleone77 Jul. 7 at 11:40 AM
$OGN Organon announces American Academy of Dermatology recommendation for Vtama cream Organon announced that Vtama cream, 1%, was granted a recommendation by the American Academy of Dermatology in their 2025 focused guideline update for the management of adults with moderate to severe atopic dermatitis. The recommendation underscores Vtama cream as an effective, steroid-free option for daily disease management, with no label warnings or precautions, no contraindications, and no restrictions on duration of use or percentage of body surface area affected.
0 · Reply
theDIOyears
theDIOyears Jul. 3 at 12:09 AM
$BIIB Are we finally in an uptrend? I hope. Biogen (BIIB)'s LEQEMBI, Is currently approved for intravenous infusion administration. The maintenance dose subcutaneous use version that can be administered at home has a tentative regulatory decision date issued by the FDA. It is called the Prescription Drug User Fee Act (PDUFA) , it is on August 31, 2025. Also remember that screening for Alzheimer's disease just got a lot easier because in May 16th 2025 the FDA approve the first and only blood screening test for Alzheimer's. They have earnings on July 31st, 2025. I'm expecting the price to bounce between the upper and lower BOLL bands in the next few weeks. God speed $VRTX $OGN $ABBV $BCRX
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 2 at 4:35 PM
Organon Drops Drug Development For Endometriosis Pain After Mid-Stage Study Fails To Show Results $OGN $AVUS $EAOR https://stocktwits.com/news/equity/markets/organon-stops-drug-development-for-endometriosis-pain-after-mid-stage-trial-fails/chF0qINRT60
0 · Reply
Value1996
Value1996 Jul. 2 at 1:23 PM
$OGN everyone is bearish because they cut their dividend. However refocusing on their balance sheet is a must. Once their debt is decreased and net assets go up they can then focus on a high dividend. They’re looking at the long term which is good to see. Plus insider buyers is always a good sign.
1 · Reply
CDMO
CDMO Jul. 2 at 11:58 AM
$OGN they literally have no pipeline and their only asset just failed. Lol
0 · Reply
theDIOyears
theDIOyears Jul. 2 at 11:33 AM
$OGN swing and miss. OG-6219 did not demonstrate improvement in moderate-to-severe endometriosis-related overall pelvic pain compared to placebo. Down day? Or unaffected ?
0 · Reply
Latest News on OGN
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

Jul 11, 2025, 9:37 AM EDT - 2 days ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

OGN COURT NOTICE: Organon & Co. Investors may have been Affected by Fraud – Contact BFA Law by the July 22 Legal Deadline (NYSE:OGN)

Jul 10, 2025, 8:18 AM EDT - 3 days ago

OGN COURT NOTICE: Organon & Co. Investors may have been Affected by Fraud – Contact BFA Law by the July 22 Legal Deadline (NYSE:OGN)

Trade Tracker: Jenny Harrington sells Organon and buys Vici Properties

Jul 8, 2025, 1:14 PM EDT - 5 days ago

Trade Tracker: Jenny Harrington sells Organon and buys Vici Properties

VICI

OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN

Jul 7, 2025, 10:10 AM EDT - 6 days ago

OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN

Organon's VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis

Jul 7, 2025, 7:30 AM EDT - 6 days ago

Organon's VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

Jul 3, 2025, 8:25 AM EDT - 10 days ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

Karolinska Development receives update from Organon concerning OG-6219

Jul 3, 2025, 1:00 AM EDT - 11 days ago

Karolinska Development receives update from Organon concerning OG-6219

Organon to halt development of endometriosis pain drug after mid-stage trial failure

Jul 2, 2025, 8:01 AM EDT - 11 days ago

Organon to halt development of endometriosis pain drug after mid-stage trial failure

Organon Provides Update on Phase 2 ELENA Proof-of-Concept Study Evaluating OG-6219 in Patients with Endometriosis-Related Pain

Jul 2, 2025, 7:30 AM EDT - 11 days ago

Organon Provides Update on Phase 2 ELENA Proof-of-Concept Study Evaluating OG-6219 in Patients with Endometriosis-Related Pain

OGN INVESTOR DEADLINE: Organon & Co. Investors with Losses may have been Affected by Fraud – Contact BFA Law by July 22 Court Deadline (NYSE:OGN)

Jun 28, 2025, 7:46 AM EDT - 15 days ago

OGN INVESTOR DEADLINE: Organon & Co. Investors with Losses may have been Affected by Fraud – Contact BFA Law by July 22 Court Deadline (NYSE:OGN)

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2025 in Organon Lawsuit - OGN

Jun 26, 2025, 9:00 AM EDT - 17 days ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2025 in Organon Lawsuit - OGN

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

Jun 24, 2025, 11:32 AM EDT - 19 days ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2025 in Organon & Co. Lawsuit - OGN

Jun 23, 2025, 9:00 AM EDT - 20 days ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2025 in Organon & Co. Lawsuit - OGN

OGN COURT REMINDER: Organon & Co. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 22 Court Deadline (NYSE:OGN)

Jun 20, 2025, 9:06 AM EDT - 23 days ago

OGN COURT REMINDER: Organon & Co. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 22 Court Deadline (NYSE:OGN)

OGN NOTICE: Did Organon & Co. Mislead Investors? Contact BFA Law by July 22 Court Deadline if You Suffered Losses (NYSE:OGN)

Jun 18, 2025, 8:38 AM EDT - 25 days ago

OGN NOTICE: Did Organon & Co. Mislead Investors? Contact BFA Law by July 22 Court Deadline if You Suffered Losses (NYSE:OGN)

Organon: A Look Beyond The Dividend Cut

Jun 18, 2025, 1:02 AM EDT - 26 days ago

Organon: A Look Beyond The Dividend Cut

OGN SHAREHOLDER REPORT: Organon & Co. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 22 Court Deadline (NYSE:OGN)

Jun 16, 2025, 8:18 AM EDT - 27 days ago

OGN SHAREHOLDER REPORT: Organon & Co. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 22 Court Deadline (NYSE:OGN)

OGN LEGAL NOTICE: Lose Money when Organon & Co. Stock Plummeted 27%? Contact BFA Law by the July 22 Court Deadline (NYSE:OGN)

Jun 10, 2025, 8:47 AM EDT - 4 weeks ago

OGN LEGAL NOTICE: Lose Money when Organon & Co. Stock Plummeted 27%? Contact BFA Law by the July 22 Court Deadline (NYSE:OGN)

OGN INVESTOR NEWS: Organon & Co. has been Sued for Securities Fraud – Contact BFA Law before July 22 Deadline (NYSE:OGN)

Jun 8, 2025, 8:18 AM EDT - 5 weeks ago

OGN INVESTOR NEWS: Organon & Co. has been Sued for Securities Fraud – Contact BFA Law before July 22 Deadline (NYSE:OGN)

Shareholders who lost money on Organon & Co. (NYSE: OGN). Should Contact Wolf Haldenstein

Jun 6, 2025, 11:51 AM EDT - 5 weeks ago

Shareholders who lost money on Organon & Co. (NYSE: OGN). Should Contact Wolf Haldenstein

OGN LAWSUIT: Organon & Co. Lawsuit Alleges Securities Fraud Violations - Investors Notified to Contact BFA Law

Jun 4, 2025, 3:46 PM EDT - 5 weeks ago

OGN LAWSUIT: Organon & Co. Lawsuit Alleges Securities Fraud Violations - Investors Notified to Contact BFA Law

OGN STOCK NOTICE: Organon & Co. has been Sued for Fraud; Investors are Notified to Contact BFA Law before July 22 Legal Deadline

Jun 3, 2025, 3:33 PM EDT - 5 weeks ago

OGN STOCK NOTICE: Organon & Co. has been Sued for Fraud; Investors are Notified to Contact BFA Law before July 22 Legal Deadline

Shareholders who lost money on Organon & Co. (NYSE: OGN) Should Contact Wolf Haldenstein

Jun 2, 2025, 3:59 PM EDT - 5 weeks ago

Shareholders who lost money on Organon & Co. (NYSE: OGN) Should Contact Wolf Haldenstein

OGN CLASS NOTICE: Organon & Co. Investors may have been Affected by Fraud – Contact BFA Law before July 22 Court Deadline (NYSE:OGN)

May 31, 2025, 7:10 AM EDT - 6 weeks ago

OGN CLASS NOTICE: Organon & Co. Investors may have been Affected by Fraud – Contact BFA Law before July 22 Court Deadline (NYSE:OGN)

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Organon & Co. (OGN)

May 27, 2025, 12:23 PM EDT - 6 weeks ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Organon & Co. (OGN)

US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection

May 27, 2025, 7:30 AM EDT - 6 weeks ago

US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection

reez007
reez007 Jul. 11 at 8:03 PM
$OGN lol someone should investigate this action. Trade up to $10.08 then just tank. Sure
0 · Reply
HoosierDaddy1728
HoosierDaddy1728 Jul. 11 at 2:30 PM
$DARE Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment Daré is eligible for continued non-dilutive funding installments of up to approximately $11.2 million Market cap $21 million FDA-approved product for the treatment of bacterial vaginosis Treatment for female sexual arousal disorder set to start sales q4 Non hormonal contraceptive in phase 3 $VERU $IFRX $BTAI $OGN
0 · Reply
theDIOyears
theDIOyears Jul. 8 at 10:57 PM
$OGN still here, still buying. Things are getting tight.
2 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Jul. 7 at 11:41 AM
$OGN Organon's VTAMA Granted Strong Recommendation By American Academy Of Dermatology In Updated 2025 Guidelines For Adult Atopic Dermatitis
0 · Reply
DonCorleone77
DonCorleone77 Jul. 7 at 11:40 AM
$OGN Organon announces American Academy of Dermatology recommendation for Vtama cream Organon announced that Vtama cream, 1%, was granted a recommendation by the American Academy of Dermatology in their 2025 focused guideline update for the management of adults with moderate to severe atopic dermatitis. The recommendation underscores Vtama cream as an effective, steroid-free option for daily disease management, with no label warnings or precautions, no contraindications, and no restrictions on duration of use or percentage of body surface area affected.
0 · Reply
theDIOyears
theDIOyears Jul. 3 at 12:09 AM
$BIIB Are we finally in an uptrend? I hope. Biogen (BIIB)'s LEQEMBI, Is currently approved for intravenous infusion administration. The maintenance dose subcutaneous use version that can be administered at home has a tentative regulatory decision date issued by the FDA. It is called the Prescription Drug User Fee Act (PDUFA) , it is on August 31, 2025. Also remember that screening for Alzheimer's disease just got a lot easier because in May 16th 2025 the FDA approve the first and only blood screening test for Alzheimer's. They have earnings on July 31st, 2025. I'm expecting the price to bounce between the upper and lower BOLL bands in the next few weeks. God speed $VRTX $OGN $ABBV $BCRX
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 2 at 4:35 PM
Organon Drops Drug Development For Endometriosis Pain After Mid-Stage Study Fails To Show Results $OGN $AVUS $EAOR https://stocktwits.com/news/equity/markets/organon-stops-drug-development-for-endometriosis-pain-after-mid-stage-trial-fails/chF0qINRT60
0 · Reply
Value1996
Value1996 Jul. 2 at 1:23 PM
$OGN everyone is bearish because they cut their dividend. However refocusing on their balance sheet is a must. Once their debt is decreased and net assets go up they can then focus on a high dividend. They’re looking at the long term which is good to see. Plus insider buyers is always a good sign.
1 · Reply
CDMO
CDMO Jul. 2 at 11:58 AM
$OGN they literally have no pipeline and their only asset just failed. Lol
0 · Reply
theDIOyears
theDIOyears Jul. 2 at 11:33 AM
$OGN swing and miss. OG-6219 did not demonstrate improvement in moderate-to-severe endometriosis-related overall pelvic pain compared to placebo. Down day? Or unaffected ?
0 · Reply
Chickenstick1
Chickenstick1 Jul. 1 at 7:56 PM
$OGN $12.5 if senate bill passes house.
0 · Reply
BuddhaLove
BuddhaLove Jun. 19 at 12:19 AM
$OGN Back in
0 · Reply
swingingtech
swingingtech Jun. 18 at 2:58 PM
$OGN $NWBI https://wallstreetwaves.com/insider-purchases-increase-for-wbiy-etf-investments/
0 · Reply
11thestate
11thestate Jun. 16 at 11:43 AM
$OGN stockholders filed a claim against Organon for allegedly misleading investors about its dividend policy and hiding plans to focus on debt reduction. You can join this case to be notified about any new information: https://11th.com/cases/organon-investor-suit
0 · Reply
tarprocapital
tarprocapital Jun. 12 at 8:14 PM
$OGN again faded, it needs a strong close to take the 11 hurdle. In my opinion the most undervalued pharmaceutical in the sector.
0 · Reply
Chickenstick1
Chickenstick1 Jun. 12 at 7:32 PM
$OGN Hate to break it to you, but the 50dma is erroneous when youre trading at below 3x earnings-- it's all about bond prices.
0 · Reply
Chickenstick1
Chickenstick1 Jun. 12 at 5:31 PM
$OGN Should be around $12.80 with this yield curve.
0 · Reply
patelmj2001
patelmj2001 Jun. 10 at 3:34 PM
$OGN train is heading to $11 load it up
0 · Reply
Chickenstick1
Chickenstick1 Jun. 9 at 7:57 PM
$OGN Adding.
0 · Reply
Quantumup
Quantumup Jun. 9 at 11:44 AM
H.C. Wainwright reiterated $ARQT Buy-$19. $OGN $ABBV $NVS $JNJ H.C. Wainwright said in its note: "The positive data from the open-label extension study reinforced the durability and favorable tolerability of Zoryve cream for the treatment of atopic dermatitis (AD), highlighting its potential as a safe and long-term treatment option for AD for patients across different ages, especially in young children. We believe these long-term data represent another key step for driving the adoption of Zoryve cream adults and children 6 years and older, and Zoryve cream 0.05% in children aged 2-5 once approved. The PDUFA date for Zoryve cream 0.05% is October 13. We are fully confident in a timely approval, given Arcutis' track record in adding label expansions for Zoryve. We reiterate our Buy rating and $19 price target for Arcutis."
0 · Reply
Chickenstick1
Chickenstick1 Jun. 4 at 5:12 PM
$OGN Adding shares to my leaps.
0 · Reply
theDIOyears
theDIOyears Jun. 2 at 8:35 PM
$OGN the momentum continues. Another day, another green hammer with a rapidly increasing lower band.
1 · Reply